Edwards Lifesciences Corporation (NYSE:EW) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Edwards Lifesciences Corporation (NYSE:EW) have earned a consensus rating of “Moderate Buy” from the twenty-five research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have issued a buy rating and three have issued a strong buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $87.0556.

EW has been the subject of several recent analyst reports. Evercore ISI set a $88.00 target price on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Wall Street Zen cut shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. JPMorgan Chase & Co. lifted their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, July 25th. Stifel Nicolaus set a $85.00 target price on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research note on Monday, September 22nd. Finally, Oppenheimer cut shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 8th.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

A number of large investors have recently modified their holdings of the company. Parkside Financial Bank & Trust raised its holdings in shares of Edwards Lifesciences by 9.8% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock worth $114,000 after purchasing an additional 130 shares during the period. Prosperity Consulting Group LLC raised its holdings in shares of Edwards Lifesciences by 3.2% in the 2nd quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock worth $337,000 after purchasing an additional 132 shares during the period. NewSquare Capital LLC raised its holdings in shares of Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after purchasing an additional 134 shares during the period. Empirical Finance LLC raised its holdings in shares of Edwards Lifesciences by 0.6% in the 2nd quarter. Empirical Finance LLC now owns 21,329 shares of the medical research company’s stock worth $1,668,000 after purchasing an additional 134 shares during the period. Finally, Arlington Trust Co LLC raised its holdings in shares of Edwards Lifesciences by 1.2% in the 1st quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company’s stock worth $804,000 after purchasing an additional 135 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Up 2.5%

Shares of Edwards Lifesciences stock opened at $74.50 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. Edwards Lifesciences has a 1 year low of $64.89 and a 1 year high of $83.00. The company has a market capitalization of $43.74 billion, a P/E ratio of 10.72, a P/E/G ratio of 3.49 and a beta of 1.05. The business has a 50 day moving average price of $77.54 and a 200 day moving average price of $76.16.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. Edwards Lifesciences’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts anticipate that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.